Non-vitamin K oral anticoagulants, also known as direct-acting oral anticoagulants (DOACs), have entered the market in 2008 with the expected breakthrough potential of circumventing limitations related to treatment with vitamin K antagonists (eg, warfarin) by virtue of their pharmacological properties. Although data derived from premarketing randomized clinical trials have largely demonstrated the clinical benefit of DOACs, especially in terms of reduced risk of intracranial bleeding, it is important to monitor the safety in the postmarketing phase, which better reflects real-world patients with comorbidities and polypharmacotherapy, in order to assess the actual risk-benefit profile. In this critical review, we aimed to evaluate the evidence on the latest debated safety issues. In the first section, we will discuss: 1) the need for pharmacovigilance (ie, the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems in the real-world setting), and 2) the importance of properly interpreting postmarketing data to avoid unnecessary alarm. In the second section, emerging and debated safety issues potentially associated with the use of DOACs in the postmarketing setting will be assessed: 1) the potential coronary risk (which emerged during the preapproval period); 2) the occurrence of liver injury (a risk undetected in clinical trials and highlighted by case reports or series); and 3) the potential for renal damage (a still unclear safety issue). It is anticipated that hepatic and renal issues still require dedicated postauthorization safety studies to ultimately assess causality.
supported the optimization in the use of DOACs through algorithm-based approaches 3, 4 ; in VTE scenario, the latest American College of Chest Physicians guideline was the first recommending DOACs over VKAs for initial and long-term VTE treatment (in the absence of cancer).
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Although data derived from premarketing randomized clinical trials have largely demonstrated the net clinical benefit of DOACs, especially in terms of reduced risk of intracranial bleeding, there is still room for improvement to optimize appropriateness and safe use of DOACs, 6 especially in evolving and emerging therapeutic indications (eg, post-acute coronary syndrome) to assess effectiveness in the real world. 7 In addition, recent postauthorization studies and a meta-analysis have highlighted the potential occurrence of unpredictable safety signals and Introduction Non-vitamin K oral anticoagulants, now referred to as direct-acting oral anticoagulants (DOACs), are candidate to changing the therapeutic scenario for patients requiring shortand long-term anticoagulation, by virtue of their pharmacological properties: fixed-dose administration, reduced likelihood of drug-drug and drug-food interactions, and no need for coagulation monitoring, as compared to vitamin K antagonists (VKAs).
1,2
In consolidated indications, namely, nonvalvular atrial fibrillation and venous thromboembolism (VTE, prevention and treatment), the current place in the therapy of dabigatran, rivaroxaban, apixaban, and edoxaban is recognized: in nonvalvular atrial fibrillation, the updated European Heart Rhythm Association (EHRA) and the American College of Cardiology (ACC) guidelines rare and unpredictable ADRs. 14, 15 It is important to remind here that these safety signals should not be viewed as unjustified alarms for clinicians (ie, they do not necessarily imply changes in prescribing practice), but should be interpreted as a research tool (ie, the first alert of potential drugevent association) to guide future research (analytical observational studies).
Coronary risk: a resolved safety issue? First suspicion and the analysis of possible biases In this section, we will describe the history of coronary risk associated with dabigatran (how and when this safety issue emerged) and guide the reader in the complex interpretation and analysis of data with the (theoretically) highest strength of evidence (ie, meta-analysis) through a perusal of the data.
The suspicion that MI could occur more frequently in patients receiving dabigatran compared with warfarin was raised by secondary results of the landmark Randomized Evaluation of Long Term Anticoagulant Therapy Trial (RE-LY), 16 which enrolled more than 18 000 patients with atrial fibrillation. MI, one of several secondary outcomes, had an annual incidence of 0.74% for patients randomized to dabigatran therapy, 150 mg twice daily, and 0.53% for warfarin, corresponding to a 38% higher risk. Since then, different meta-analyses have been published with discordant results, thus causing uncertainty as to this putative association. In particular, Uchino et al 17 performed a fixed-effects Mantel-Haenszel meta-analysis of 7 noninferiority RCTs comparing dabigatran with warfarin and found a 33% higher risk of MI or acute coronary syndrome (ACS). Several methodological pitfalls were elegantly highlighted by Correia and Lopes, 18 who hypothesized the concept of "metaillusion": the fact that MI was a secondary endpoint (more prone to result from chance) and, especially, the remarkable influence of RE-LY may have strongly guided the meta-analytic process (ie, the relative weight of RE-LY largely exceeded that of all other RCTs). To support their theory, they meta-analyzed the same trials except RE-LY through a random -effect model, which yielded a statistically nonsignificant result (odds ratio [OR], 1.2; 95% confidence interval [CI], 0.66-1.9). We would like to remark that the RE-LY's definition of MI was as follows: "Clinical MI was defined as the presence of at least two of the following three criteria: 1) Typical prolonged severe chest pain or related symptoms or signs (eg, ST changes or Twave inversion in the ECG); 2) Suggestive of MI elevation of troponin or creatine kinase-MB to more than the upper level of normal, or if creatine kinase-MB was elevated at baseline, reevaluation to 50% increase above the previous level; 3) Development of significant Q waves in at least two adjacent ECG leads".
16 Therefore, even nonspecific cardiac disorders resulting in the elevation of creatine kinase-MB levels and chest pain might be included according to these criteria, with a potential overestimation of the actual cases of MI. a higher than expected incidence of gastrointestinal bleeding, 8, 9 which requires further evaluation and integration with real-world data to assess their actual risk-benefit profile.
In this context, the aim of this review was to critically evaluate the evidence on the latest debated safety issues (ie, coronary risk, liver and renal injury), especially considering real-world data.
Lessons from pharmacovigilance: the road towards appropriateness Pharmacovigilance has been defined by the World Health Organization (WHO) as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drugrelated problems". 10 The current era has started with the pharmacovigilance legislation (Regulation [EU] No 1235/2010 and Directive 2010/84/ EU), in force as of July 2012, and aims to promote and protect public health by reducing the burden of adverse drug reactions (ADRs) and optimizing the use of medicines. This can be achieved through heterogeneous sources of data, from randomized clinical trials (RCTs) to analytical observational studies, but also from health forums of patients. 11 Although it is universally accepted that RCTs represent the highest level of evidence (and usually do have internal validity), too stringent enrollment criteria and short-term follow-up do not allow generalizability and full translation of results into clinical practice. Moreover, safety is rarely tested as a prespecified endpoint during the premarketing phase. Therefore, postmarketing safety studies are recognized as a key tool to investigate the real-world usage patterns of drugs, where multimorbidities and polypharmacology exist, in order to cover the whole spectrum of the evidence. This is particularly the case for patients requiring DOAC administration, who are likely to be elderly, with a various degree of renal impairment, affected by multifactorial cardiovascular dysfunctions (eg, previous myocardial infarction [MI] or chronic heart failure) and other diseases (eg, cancer), as well as requiring multiple drugs likely to result in interactions. All these aspects increase the risk of predictable (ie, bleeding) and unpredictable ADRs. Different examples have been recently presented in the literature, indicating that, for both dabigatran and rivaroxaban, a large proportion of spontaneous reports of ADRs (from 34% to 89%) were associated with the use of concomitant medicines with bleeding potential.
These findings once more call for active vigilance by prescribers and careful assessment of the patient's comorbidities and comedications to minimize risks in routine clinical practice.
12,13 When properly designed (ie, with a clear research question, keeping in mind major bias and addressing major confounders), reported with transparency and disseminated through a balanced view, these studies may highlight possible foci of inappropriateness and support a safe use of drugs through early identification of safety signals, especially for values (ranging from 0.003 to 0.025) obtained when the other studies were excluded. Interestingly enough, a higher P value was also accepted when RE-MEDY was excluded (0.025). Furthermore, the authors report that, as in most trials the definition of MI was not available, they adjudicated all ACSs as MI if not stated otherwise, admitting that this might have led to overestimation of the rate of MI.
We believe that statistical incoherence in reporting results, lack of individual patient data, and unspecific outcome definition might have biased the conclusions drawn by the authors (ie, significantly increased risk of MI).
Clemens et al 20 meta-analyzed only 4 RCTs, all of which reported MI as a secondary outcome: RE-LY, RE-MEDY, and RECOVER I and II. The RE-LY and RE-MEDY trials strongly affected the meta-analysis as they enlisted roughly 4 times as many patients as RECOVER I and II. The reported OR was 1.42 (95% CI, 1.07-1.88), which
Moving towards a more critical overview of discordant meta-analyses: a meta-delusion This intriguing scenario prompted us to test other discordant meta-analyses for potential methodological bias, paying attention to sensitivity analyses. We performed a search in MEDLINE (free text strategy "dabigatran and myocardial infarction") and retrieved 2 additional systematic reviews directly comparing dabigatran with VKAs. A synopsis is provided in TABLE 1.
Douxfils et al
19 considered the potential influence of RE-LY on results and performed additional analyses, but firmly stated that "overall one-way sensitivity analysis shows that similar results are obtained regardless of which study is excluded from the primary analysis, even when RE-LY is removed". However, a supplementary table reported that RE-LY removal resulted in a Peto OR of 1.457 (95% CI, 1.002-2.118) with a P value of 0.049, which is within the threshold of statistical significance, as compared to other P Dabigatran is associated with a significantly increased risk of MI.
These analyses suggest a more protective effect of well-controlled warfarin …. These data suggest that myocardial infarction is not an adverse drug reaction associated with the use of dabigatran.
a 257 total events/20 000 total patients × 100 = 1.28; 195 events in RE-LY/20 000 total patients × 100 = 0.975; 0.975/1.28 × 100 = 76% b 213 total events/16 073 total patients × 100 = 1.32; 195 events in RE-LY/16 073 total patients × 100 = 1.21; 1.21/1.32 × 100 = 91.66%
Abbreviations: ACS, acute coronary syndrome; MI, myocardial infarction; OR, odds ratio; RCTs, randomized clinical trials attracting multidisciplinary interest, because of the imperfect prediction of preclinical assays and potential underestimation in clinical phases. 35 The risk of DILI associated with DOACs is a recent safety issue, which was undetected in preclinical, underestimated in clinical phases, and only emerged during postmarketing use (FIGURE 1). In fact, even when suspected to be drug-related, the diagnosis is a current clinical challenge because a number of alternative causes must be excluded.
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It is important to remind that patients with active liver disease were not enrolled in landmark studies: liver impairment may in fact per se increase the risk of clinically relevant bleeding and increase the drug-related toxicity, considering that DOACs undergo hepatic metabolism. Therefore, current summaries of the product characteristics (SPCs) do not recommend use of DOACs in patients with liver impairment, and rivaroxaban is even contraindicated in cirrhotic patients (hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C).
Based on premarketing RCTs, DOACs can cause a transient elevation of hepatic transaminase levels in about 2% of the treated patients enrolled in phase III studies (uncommon in terms of frequency). 37 However, the idiosyncratic nature of DILI, including the undefined role of patient-and drug-related risk factors (exemplified by the case of ximelagatran) 38 and relevant limited capacity to predict its occurrence in the real-world scenario make postmarketing surveillance crucial to identify these off-target side effects. In particular, case reports still represent a key source of evidence to support regulatory measures, including drug withdrawals. 39 A number of case reports, case series, and analyses of pharmacovigilance databases has been accrued in the last year and suggest that DOACs are associated with a rare but clinically relevant risk of hepatotoxicity. 40 An updated free text search in MEDLINE (as of May 31, 2016) yielded 13 publications: 10 case reports/case series (28 patients), 1 review providing the overall reporting frequency from international spontaneous reporting systems (SRSs), 1 pharmacovigilance study (disproportionality analysis) on the US Food and Drug Administration SRS (called FAERS), and 1 systematic review with meta-analysis of RCTs (Supplementary material online, Table S1 ).
41-53
As expected, the meta-analytic approach by Caldeira et al, 52 did not highlight an increased risk, although a trend towards statistical significance emerged for rivaroxaban. However, data from large international SRSs highlighted that rivaroxaban is reported to cause liver damage in 3.7% to 3.9% of total reports, whereas 1.7% to 1.8% of cases submitted for dabigatran mentioned potential liver injury. 48, 49 Rivaroxaban is identified as the suspect drug in all but one DILI reports published so far: most patients are characterized by hyperbilirubinemia with hepatocellular or mixed liver injury pattern, usually recovered
uous outcome definition and a possible imbalance in data interpretation. Notably, the authors stated that the increase in MI events with dabigatran is due to a protective effect of warfarin against MI. To support this claim, they quoted 3 articles: the RCT SPORTIF III (comparing ximelagatran with warfarin), 21 a meta-analysis (combining RE-LY, SPORTIF-III, and SPORTIF-IV, and comparing ximelagatran with warfarin), and AMADEUS (comparing idraparinux with warfarin). 22 The third study quoted by Clemens et al 20 did not compare warfarin with DOACs and concluded that warfarin use at discharge was superior to no warfarin (a pool of drugs which included aspirin and ticlopidine/clopidogrel) in preventing a second hit in post-MI patients with atrial fibrillation. 23 For the sake of completeness, we retrieved 3 additional meta-analyses that did not fulfill our inclusion criteria. One of them compared apixaban with different controls and did not identify an increased risk of MI (OR, 0.92; 95% CI, 0.71-1.20, as compared to other anticoagulants). 24 The other two meta-analyses indirectly compared DOACs and were concordant in concluding that dabigatran was associated with an increased risk as compared to rivaroxaban and apixaban.
25,26 However, it should be recognized that these data are mainly driven by studies in population with ACS, especially by the ATLAS ACS 2 -TIMI 51 trial 27 for rivaroxaban, which was pivotal for rivaroxaban approval in this indication.
In summary, the confusion from discordant meta-analyses has now been pruned, and we take this opportunity to call once more for proper conduction, interpretation, and communication of data derived from safety meta-analysis in order to avoid unnecessary alarm 28-30 and avoid the possibility of a meta-delusion (ie, the misinterpretation of findings that are strongly influenced by residual confounders). The current body of evidence from RCTs does not support an increased risk of MI with dabigatran (it is of borderline statistical significance and largely guided by the RE-LY study).
31 More importantly, these preapproval data (based on phase III studies) actually conflict with postmarketing cohort studies (phase IV), which failed to find an increased coronary risk 32 and even documented lower rates of MI in different propensity-matched comparisons against warfarin. 33,34 In addition, no sound pharmacologic mechanism supports the hypothesis of dabigatran-related myocardial adverse events. This is just another example of how safety signals should be handled in order to avoid unnecessary alarm for clinicians.
Liver risk: a safety issue that should not be overlooked
Drug-induced liver injury (DILI) is a leading cause of drug withdrawal worldwide and a safety topic therapies and, eventually, interrupt drug administration in patients with severe hepatotoxicity. It is also important to report suspicious cases to the national pharmacovigilance services in order to improve our understanding of DILI, especially for recently marketed apixaban and edoxaban.
The research agenda should address the issue of class effect and the mechanistic basis of DILI. In fact, although hepatotoxicity (associated with DOACs) is deemed to be idiosyncratic (ie, it may occur at therapeutic doses and cannot be explained by the pharmacological action of these drugs), the latest evidence has suggested that both host-and drug-related risk factors are likely to interact in the occurrence of DILI. 54 Among the latter, daily dose, lipophilicity, metabolic pathway mediated by cytochromes, and structural moieties with the formation of reactive metabolism have been proposed to be strong predictors of the risk in humans. 55 Notably, apixaban, rivaroxaban, and dabigatran contain structural moieties, although they are not clearly involved in the formation of known hepatotoxic reactive metabolites.
56-58 Therefore, chemical and pharmacokinetic features deserve further analyses before being considered to account for the increased reporting frequency observed for rivaroxaban. In fact, a recent case report described a 67-year-old male with atrial fibrillation receiving rivaroxaban who developed a 16-fold elevation in alanine transaminase levels; a switch to apixaban resulted in rapid resolution of laboratory rapidly after drug discontinuation, but hepatic failure has also been described. It is interesting to note that 4 case reports/case series came from France and 2 from Switzerland. This suggests that a local reporting pattern should be further investigated, as it may have a role as a predisposing factor in the occurrence of the event. In addition, the majority of these patients have undergone knee surgery or experienced venous thrombotic events, suggesting that orthopedic and related prothrombotic conditions (instead of atrial fibrillation) may increase patient's susceptibility to DILI.
Although hepatic events associated with DOACs are clearly rare, vigilance should be maintained by both clinicians and pharmacovigilance experts. In fact, although incidence and relative risk cannot be derived from SRSs, the estimated risk could not be as uncommon as stated in the SPCs. Based on this reporting frequency, recommending close monitoring of liver function in patients treated with DOACs is not justified. However, the time-to-onset from published case reports suggests that early evaluation of hepatic enzymes (ie, within the first month) may be considered at least in patients under complex treatment regimen with comorbidities; subsequently, liver function can be monitored on a yearly basis. Patients should be instructed to timely communicate early clinical signs and symptoms to the physician, who should consider, on a case-by-case basis, the role of DOACs as well as concomitant that patient data on AKI etiology were not available. Data on dabigatran are much more scarce, although case reports have been documented, including reports of fatal toxicity. 66 The pathophysiological mechanisms underlying warfarin-and dabigatran-related nephrotoxicity have been investigated by Ryan et al 67 and Narasimha Krishna et al, 68 who confirmed that they resemble each other in clinical and pathological features but differ in mechanisms. Warfarin might cause damage by inhibiting GAS6 and matrix G1a protein, the vitamin K-dependent inhibitors of smooth muscle cell migration, mesangial cell proliferation, and vascular calcification. The mechanistic basis of dabigatran-related nephrotoxicity, as a non-vitamin K anticoagulant, follows a different pathway. Ryan et al 67 showed that thrombin inhibition causes a decreased thrombin activity resulting in decreased protease-activated receptor 1 activity (thrombin GPCR is expressed on endothelial cells), and this is thought to alter the glomerular filtration barrier and disrupt the endothelial lining integrity. 67 A recent meta-analysis of 10 RCTs comparing DOACs and VKAs found no differences in the risk of renal failure associated with the use of DOACs, although rivaroxaban shows a trend for increased risk and an increased risk of creatinine elevation (relative risk, 1.25; 95% CI, 1.08-1.45).
69 As compared to DILI, it must be emphasized that no reports have been published to date suggesting the occurrence of AKI with rivaroxaban and apixaban, with only 1 nonfatal case report for dabigatran. (TABLE 2) . Overall, the reporting rate of liver, renal, and myocardial failures (serious acute events) is very low as compared to other ADRs, thus suggesting the rarity of these events in clinical practice. However, the frequency of renal injury for dabigatran (2.5%-3.5%) warrants a case-by-case analysis. In fact, these data must be interpreted very cautiously, and a direct association cannot be inferred because of the inherent limitations (mainly underreporting and the lack of "nonexposed" patients). These data primarily aim at identifying further areas of research in pharmacovigilance. In conclusion, we offer the following take-home messages: 1 The current risk-benefit profile of DOACs is largely positive, but the magnitude of these ADRs in terms of clinical and epidemiological impact is abnormalities, thus suggesting that rivaroxaban's mechanism of hepatotoxicity may be unrelated to its pharmacologic action. 59 In summary, chemists, pharmacologists, and clinicians should join efforts to improve prediction, assess actual mechanistic basis of DILI occurrence, and establish causality.
Renal risk: a still uncertain multifaceted issue Before discussing the risk of DOACs in precipitating renal dysfunction, we briefly mention a debated aspect, that is, appropriate prescribing in patients with renal impairment. In this setting, assessment of kidney function is important to estimate their potential accumulation, which may result in increased risk of bleeding, and dose adjustment may be required depending on the extent of renal impairment and relevant kidney clearance of each DOAC.
In fact, clinicians should remind that all DOACs depend to some extent on renal function for clearance, with dabigatran being 80% excreted via the kidney. This is especially critical in patients with advanced chronic kidney disease (CKD) and endstage renal disease requiring dialysis. These patients were excluded from all pivotal phase III trials, thus current SPCs do not recommend their use when creatinine clearance is below 15 ml/min. The reader may refer to the 2015 EHRA practical guide, which suggested a 3-month interval monitoring in elderly patients, 3 and to recent review articles, which supported close monitoring in elderly patients (at risk of tubule-interstitial injury) with comorbidities and polypharmacology, especially at the beginning of the therapy, in case of long-term use, concomitant interacting/nephrotoxic drugs (eg, nonsteroidal anti-inflammatory drugs), and incidental infections that may increase the patient's susceptibility to renal injury and bleeding occurrence. 60, 61 The preference over one DOAC versus another is still a matter of debate and the therapeutic choice should be made on a case-by-case basis and likely to be guided mainly by clinical experience.
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Anticoagulant-related nephropathy The risk of anticoagulant-related nephropathy is a recently identified clinical entity defined as an acute kidney injury (AKI), without other obvious etiology, in the setting of an international normalized ratio (INR) greater than 3.0.
63 First characterized as warfarin-related nephropathy by Brodsky et al 64 in 2009, it has been also related to dabigatran and, possibly, other DOACs. Its incidence and prevalence are difficult to be precisely estimated, although the overall evidence (mainly based on case reports and case series) suggests it is a rare clinical event. Brodsky et al 65 reported a mean incidence of 20.5% in the whole cohort of patients with an INR exceeding 3.0 and serum creatinine levels measured, rising to 33.0% in patients with CKD, while remaining at a level of 16.5% in the non-CKD cohort. These data might unduly overestimate the actual epidemiological dimension, given 2 The coronary risk, described for dabigatran, is not supported by a critical evaluation of the evidence, mainly derived from RCTs. High-risk patients should be investigated to finally exclude this risk, although recent cohort studies have consistently demonstrated a reduced risk of MI in real-world clinical practice. 3 The unpredictable nature of liver damage by DOACs, especially for rivaroxaban, emerged from postmarketing real-world data and calls for awareness by clinicians, who should consider DOACs among the differential diagnoses and report suspected drug-related hepatic injuries to regulatory authorities, as well as for preclinical studies to gain insight into mechanistic basis and predict drug-related features likely to increase the occurrence of DILI in humans. Clinicians should consider to assess liver function at the beginning of administration (within the first month) and then on a yearly basis, at least in patients under a complex treatment regimen with comorbidities. 4 The potential for renal damage (ie, the possibility of precipitating kidney dysfunction in patients with or without renal impairment) remains insufficiently characterized and warrants observational data to validate the pharmacokinetic hypothesis that renal clearance may compromise clinical effectiveness and safety, and to confirm the mechanistic basis of anticoagulant-related nephropathy and actual epidemiological magnitude.
Current clinical and research efforts should be directed towards defining the precise place in therapy of DOACs in frail patients (severe renal impairment with comorbidities and polypharmacology), especially in light of evolving therapeutic uses (eg, heparin-induced thrombocytopenia, cancer, coronary artery diseases). 7
